Abstract
After decades of sometimes fierce debate about the advantages and disadvantages of glucocorticoids, an age of convergence has been reached. Current recommendations for the management of diseases such as rheumatoid arthritis (RA), polymyalgia rheumatica and large vessel vasculitis reflect the current consensus that as much glucocorticoid as necessary, but as little as possible, should be used. Over the past few years, a range of glucocorticoid-sparing strategies have been developed, as have tools to improve the management of this therapy. A comprehensive view of glucocorticoid-induced osteoporosis has also emerged that recognizes that bone fragility is not solely determined by the dose and duration of glucocorticoid treatment. Nevertheless, open questions remain around whether long-term use of very low doses of glucocorticoids is a realistic option for patients with RA and whether the search for innovative glucocorticoids or glucocorticoid receptor ligands with improved benefit-to-risk ratios will ultimately be successful.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Waljee, A. K. et al. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ 357, j1415 (2017).
Hench, P. S., Kendall, E. C., Slocumb, C. H. & Polley, H. F. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Proc. Staff Meet. Mayo Clin. 24, 181–197 (1949).
Bunim, J. J., Pechet, M. M. & Bollet, A. J. Studies on metacortandralone and metacortandracin in rheumatoid arthritis; antirheumatic potency, metabolic effects, and hormonal properties. J. Am. Med. Assoc. 157, 311–318 (1955).
Strehl, C. et al. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Ann. Rheum. Dis. 75, 952–957 (2016).
Buttgereit, F. et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann. Rheum. Dis. 61, 718–722 (2002).
Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann. Rheum. Dis. 76, 960–977 (2017).
Miloslavsky, E. M. et al. Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis. Ann. Rheum. Dis. 76, 543–546 (2017).
Buttgereit, F. et al. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet 371, 205–214 (2008).
Buttgereit, F. et al. Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis. Ann. Rheum. Dis. 69, 1275–1280 (2010).
Buttgereit, F. et al. Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Ann. Rheum. Dis. 72, 204–210 (2013).
Buttgereit, F. et al. Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb study. RMD Open 5, e000889 (2019).
Kirwan, J. R., Bijlsma, J. W., Boers, M. & Shea, B. J. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst. Rev. 1, CD006356 (2007).
Buttgereit, F., Smolen, J. S., Coogan, A. N. & Cajochen, C. Clocking in: chronobiology in rheumatoid arthritis. Nat. Rev. Rheumatol. 11, 349–356 (2015).
Buttgereit, F., Dejaco, C., Matteson, E. L. & Dasgupta, B. Polymyalgia rheumatica and giant cell arteritis: a systematic review. JAMA 315, 2442–2458 (2016).
Boers, M., Kirwan, J. R. & Bijlsma, J. W. American College of Rheumatology treatment guidelines continue to omit guidance on glucocorticoids: comment on the article by Singh et al. Arthritis Care Res. 64, 1622 (2012).
Saag, K. G. et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 59, 762–784 (2008).
Singh, J. A. et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 64, 625–639 (2012).
Singh, J. A. et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 68, 1–25 (2016).
Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann. Rheum. Dis. 69, 964–975 (2010).
Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann. Rheum. Dis. 73, 492–509 (2014).
Ramiro, S. et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann. Rheum. Dis. 76, 1101–1136 (2017).
Chatzidionysiou, K. et al. Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann. Rheum. Dis. 76, 1102–1107 (2017).
Buttgereit, F. & Bijlsma, J. W. Glucocorticoids in rheumatoid arthritis: the picture is shaping up. Ann. Rheum. Dis. 76, 1785–1787 (2017).
Roubille, C. et al. Seven-year tolerability profile of glucocorticoids use in early rheumatoid arthritis: data from the ESPOIR cohort. Ann. Rheum. Dis. 76, 1797–1802 (2017).
Albrecht, K. et al. Clinical remission in rheumatoid arthritis. Data from the early arthritis cohort study CAPEA [German]. Z. Rheumatol. 75, 90–96 (2016).
Black, R. J. et al. Factors associated with oral glucocorticoid use in patients with rheumatoid arthritis: a drug use study from a prospective national biologics registry. Arthritis Res. Ther. 19, 253 (2017).
Albrecht, K. et al. Medical treatment of rheumatoid arthritis in 2014: current data from the German Collaborative Arthritis Centers [German]. Z. Rheumatol. 76, 50–57 (2017).
Burmester, G. et al. Randomized controlled 24-week trial evaluating the safety and efficacy of blinded tapering versus continuation of long-term prednisone (5 mg/d) in patients with rheumatoid arthritis who achieved low disease activity or remission on tocilizumab [abstract]. Ann. Rheum. Dis. 78 Suppl. 2, 84−85 (2019).
Dejaco, C. et al. 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann. Rheum. Dis. 74, 1799–1807 (2015).
Shbeeb, I., Challah, D., Raheel, S., Crowson, C. S. & Matteson, E. L. Comparable rates of glucocorticoid-associated adverse events in patients with polymyalgia rheumatica and comorbidities in the general population. Arthritis Care Res. 70, 643–647 (2018).
Hellmich, B. et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann. Rheum. Dis. 79, 19–30 (2020).
Strehl, C., van der Goes, M. C., Bijlsma, J. W., Jacobs, J. W. & Buttgereit, F. Glucocorticoid-targeted therapies for the treatment of rheumatoid arthritis. Expert Opin. Investig. Drugs 26, 187–195 (2017).
Matteson, E. L., Buttgereit, F., Dejaco, C. & Dasgupta, B. Glucocorticoids for management of polymyalgia rheumatica and giant cell arteritis. Rheum Dis. Clin. North Am. 42, 75–90 (2016).
van der Goes, M. C. et al. Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann. Rheum. Dis. 69, 1015–1021 (2010).
Movahedi, M. et al. Oral glucocorticoid therapy and all-cause and cause-specific mortality in patients with rheumatoid arthritis: a retrospective cohort study. Eur. J. Epidemiol. 31, 1045–1055 (2016).
Ton, F. N., Gunawardene, S. C., Lee, H. & Neer, R. M. Effects of low-dose prednisone on bone metabolism. J. Bone Miner. Res. 20, 464–470 (2005).
Rizzoli, R. & Biver, E. Glucocorticoid-induced osteoporosis: who to treat with what agent? Nat. Rev. Rheumatol. 11, 98–109 (2015).
Briot, K., Geusens, P., Em Bultink, I., Lems, W. F. & Roux, C. Inflammatory diseases and bone fragility. Osteoporos. Int. 28, 3301–3314 (2017).
Ozen, G., Pedro, S., Wolfe, F. & Michaud, K. Medications associated with fracture risk in patients with rheumatoid arthritis. Ann. Rheum. Dis. 78, 1041–1047 (2019).
Buttgereit, F. Do the treatment with glucocorticoids and/or the disease itself drive the impairment in glucose metabolism in patients with rheumatoid arthritis? Ann. Rheum. Dis. 70, 1881–1883 (2011).
Listing, J., Gerhold, K. & Zink, A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology 52, 53–61 (2013).
Stone, J. H. et al. Trial of tocilizumab in giant-cell arteritis. N. Engl. J. Med. 377, 317–328 (2017).
Buttgereit, F., Brand, M. D. & Burmester, G. R. Equivalent doses and relative drug potencies for non-genomic glucocorticoid effects: a novel glucocorticoid hierarchy. Biochem. Pharmacol. 58, 363–368 (1999).
Dineen, R., Stewart, P. M. & Sherlock, M. Factors impacting on the action of glucocorticoids in patients receiving glucocorticoid therapy. Clin. Endocrinol. 90, 3–14 (2019).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02997605 (2019).
Unizony, S. H. et al. Design of the tocilizumab in giant cell arteritis trial. Int. J. Rheumatol. 2013, 912562 (2013).
Da Silva, J. A. et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann. Rheum. Dis. 65, 285–293 (2006).
Alten, R. et al. Hypothalamus-pituitary-adrenal axis function in patients with rheumatoid arthritis treated with nighttime-release prednisone. J. Rheumatol. 37, 2025–2031 (2010).
Alten, R., Grahn, A., Holt, R. J., Rice, P. & Buttgereit, F. Delayed-release prednisone improves fatigue and health-related quality of life: findings from the CAPRA-2 double-blind randomised study in rheumatoid arthritis. RMD Open 1, e000134 (2015).
Alten, R. et al. Morning stiffness response with delayed-release prednisone after ineffective course of immediate-release prednisone. Scand. J. Rheumatol. 44, 354–358 (2015).
Safy, M. et al. Efficacy and safety of selective glucocorticoid receptor modulators in comparison to glucocorticoids in arthritis, a systematic review. PLoS One 12, e0188810 (2017).
Buttgereit, F., Bijlsma, J. W. J. & Strehl, C. Will we ever have better glucocorticoids? Clin. Immunol. 186, 64–66 (2018).
Santiago, T. & da Silva, J. A. Safety of glucocorticoids in rheumatoid arthritis: evidence from recent clinical trials. Neuroimmunomodulation 22, 57–65 (2015).
van Sijl, A. M., Boers, M., Voskuyl, A. E. & Nurmohamed, M. T. Confounding by indication probably distorts the relationship between steroid use and cardiovascular disease in rheumatoid arthritis: results from a prospective cohort study. PLoS One 9, e87965 (2014).
Reinau, D. et al. Glucocorticoids and the risk of peptic ulcer bleeding: case-control analysis based on Swiss claims data. Drug Saf. 41, 725–730 (2018).
Blavnsfeldt, A. G. et al. The effect of glucocorticoids on bone mineral density in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized, controlled trials. Bone 114, 172–180 (2018).
Mendoza-Pinto, C. et al. Bone mineral density and vertebral fractures in patients with systemic lupus erythematosus: a systematic review and meta-regression. PLoS One 13, e0196113 (2018).
Petri, H., Nevitt, A., Sarsour, K., Napalkov, P. & Collinson, N. Incidence of giant cell arteritis and characteristics of patients: data-driven analysis of comorbidities. Arthritis Care Res. 67, 390–395 (2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
F.B. declares that he has received consultancy fees, honoraria, travel expenses and grant support from Horizon Pharma, Mundipharma, Pfizer and Roche. The work of F.B. in the ongoing Rh-GIOP study (Glucocorticoid-induced osteoporosis in patients with chronic inflammatory rheumatic diseases or psoriasis; NCT02719314) is supported by joint funding from Amgen, BMS, Celgene, Generic Assays, GSK, Hexal, Horizon, Lilly, Medac, Mundipharma, Novartis, Pfizer, Roche and Sanofi.
Additional information
Peer review information
Nature Reviews Rheumatology thanks P. Verschueren, E. Matteson and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Glossary
- Amaurosis fugax
-
A painless temporary loss of vision in one or both eyes.
- Bridging therapy
-
The use of glucocorticoids in patients who initiate conventional synthetic DMARD treatment or need to be switched to another such drug to bridge the period until treatment with the new agent has become effective.
- Chronobiology
-
A branch of biology concerned with cyclical physiological phenomena.
- Cushingoid habitus
-
A physique that resembles that observed in individuals with Cushing disease (a condition in which the pituitary gland releases too much adrenocorticotropic hormone), but is caused by treatment with synthetic glucocorticoids.
- Pulse therapy
-
Treatment with >250 mg prednisone equivalent daily for 1 or a few days.
Rights and permissions
About this article
Cite this article
Buttgereit, F. Views on glucocorticoid therapy in rheumatology: the age of convergence. Nat Rev Rheumatol 16, 239–246 (2020). https://doi.org/10.1038/s41584-020-0370-z
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-020-0370-z
This article is cited by
-
Targeted therapies of inflammatory diseases with intracellularly gelated macrophages in mice and rats
Nature Communications (2024)
-
Antiviral Nanomedicine-Based Approaches against Epstein-Barr Virus Infection
Current Treatment Options in Infectious Diseases (2024)
-
Association of sarcopenia and vitamin D deficiency with glucocorticoid-induced osteoporosis in Chinese patients with rheumatoid arthritis
Clinical Rheumatology (2024)
-
Combining nanotechnology with monoclonal antibody drugs for rheumatoid arthritis treatments
Journal of Nanobiotechnology (2023)
-
No association between methotrexate and impaired bone mineral density in a cohort of patients with polymyalgia rheumatica, giant cell arteritis, granulomatosis with polyangiitis and other vasculitides—a cross-sectional analysis with dose–response analyses
Rheumatology International (2023)